2025年底，一组统计数据的公布令我倍感振奋：厦门生物医药港的产业规模，"十四五"期间年均值约 390亿元，较"十三五"年均值增长超80%；连续7年稳居全国生物医药产业园区综合竞争力排行榜前15 强，2022年更是跻身全国前10。一组组数据背后，是营商环境不断优化、各类要素畅通流动的有力支 撑。 我生活和工作在福建生物医药产业的核心承载区——位于厦门市海沧区的厦门生物医药港。在这里，我 不仅见证了全球生物医药产业的变迁，直面其中蕴藏的机遇与挑战，更切身感受到高水平社会主义市场 经济体制的重要意义。 （文章来源：经济日报） 过去5年，我所在的生物科技领域，国产创新成果好消息不断。以厦门生物医药港为例，这里既打造 出"研发创新—孵化器—加速器—产业园"的完整产业链条，还建设起诊断试剂、植介入器械等医疗器械 产业集群，展现出在基因工程疫苗、蛋白药物、创新化学药、高端保健品等领域的强劲研发与转化能 力，持续提升创新层级，展现出"产业特色鲜明、创新能力强劲、要素资源齐全"的优势亮点。 过去5年，众多科研团队与相关企业在各方护航之下奋勇进取，努力打造行业标杆，彰显出海沧区新兴 产业培育的丰硕成果。目前，已有530余家生物 ...

Core Viewpoint - Guangdong Province leads the innovation in the medical device industry with 8,200 research and production enterprises, reflecting the rapid development of high-performance medical device technology in China [1][4]. Group 1: Industry Overview - The forum held in Guangzhou focused on the integration of medical and engineering fields, discussing the latest advancements and challenges in high-performance medical devices amid complex international circumstances [1]. - By 2030, one-sixth of the global population will be over 60 years old, with China expected to have 310 million people aged 60 and above by the end of 2024, indicating a growing demand for diverse and high-quality medical devices [2][3]. Group 2: Market Dynamics - The domestic market for medical devices has seen a significant shift, with foreign companies' market share decreasing from over 90% in 2015 to 65% in 2023, highlighting the increasing competitiveness of domestic enterprises [3]. - The number of domestic medical device manufacturers has surged from 16,356 in 2018 to 34,635 by mid-2023, marking an increase of 111.8% [3]. Group 3: Technological Advancements - The development of artificial intelligence in medical devices is accelerating, with approximately one-third of AI-based medical devices approved in 2024 directly applying AI technology, particularly in medical imaging [3]. Group 4: Strategic Recommendations - Guangdong Province is encouraged to enhance scientific and technological innovation, improve talent cultivation in the medical device sector, and optimize the development ecosystem for the industry [4].

Group 1 - The core viewpoint of the article highlights the emergence of 80 early-stage entrepreneurial companies in China with cutting-edge and disruptive technological innovation capabilities, with 21 of them located in Jiangsu, making it one of the top regions alongside Beijing [1][2] - Jiangsu's listed companies are characterized by their strong hard technology focus, with over half originating from research universities, research institutions, and new R&D organizations, indicating a high potential for commercialization [1][2] - The selected companies are primarily concentrated in fields such as AI and robotics, innovative pharmaceuticals, and medical devices, aiming to achieve breakthroughs in key national strategic areas and tackle critical technological challenges [1][2] Group 2 - The "Future Star" companies are actively innovating across 35 sectors, including embodied intelligence, implantable devices, commercial satellites, and new drug development service platforms, with over 10 companies in the embodied intelligence sector [2] - The founding teams of these companies typically possess a high level of expertise, combining backgrounds of "technical experts" from academic institutions and large enterprises with "entrepreneurs" who are often serial founders or executives from major companies [2] - The selection process for the list involved recommendations from nearly 100 leading technology investment and incubation institutions, followed by expert evaluations [2]